Technical Analysis for ZIOP - ZIOPHARM Oncology Inc

Grade Last Price % Change Price Change
grade C 5.06 -0.20% -0.01
ZIOP closed down 0.2 percent on Friday, August 16, 2019, on 57 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical ZIOP trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Doji - Bullish? Reversal 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Buy Signal Bullish -0.20%
NR7 Range Contraction -0.20%

Older signals for ZIOP ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on the development and commercialization of new cancer therapies. Its lead candidate, Palifosfamide (ZIO-201), a DNA alkylating agent, is under Phase III clinical trial for the treatment of first-line metastatic soft tissue sarcoma; and is in Phase III clinical trial for first-line metastatic small cell lung cancer. The company's portfolio of clinical-stage product candidates also includes ZIN-CTI-001, which is in Phase Ib clinical trial in patients with metastatic melanoma; ZIN-ATI-001, which is in Phase 1b clinical trial in patients with late-stage melanoma; Indibulin (ZIO-301), a novel, tubulin binding agent in Phase I/II clinical trial in metastatic breast cancer; and Darinaparsin (ZIO-101), a novel mitochondrial-and hedgehog-targeted agent. In addition, it is developing oral capsule form of palifosfamide. The company has an exclusive channel partner agreement with Intrexon Corporation in which the company uses Intrexon Corporation technology directed towards in vivo expression of effectors in connection with the development of ZIN-CTI-001 and ZIN-ATI-001. ZIOPHARM Oncology, Inc. was founded in 2003 and is headquartered in New York, New York.
Medicine Biopharmaceutical Cancer Melanoma Cancer Therapies Metastatic Breast Cancer Metastatic Melanoma Metastatic Small Cell Lung Cancer Neoplasms
Is ZIOP a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 7.25
52 Week Low 1.56
Average Volume 2,252,871
200-Day Moving Average 3.8429
50-Day Moving Average 5.6588
20-Day Moving Average 5.8395
10-Day Moving Average 5.531
Average True Range 0.3523
ADX 19.14
+DI 17.759
-DI 26.5117
Chandelier Exit (Long, 3 ATRs ) 6.1931
Chandelier Exit (Short, 3 ATRs ) 6.0069
Upper Bollinger Band 6.9639
Lower Bollinger Band 4.7151
Percent B (%b) 0.15
BandWidth 38.510146
MACD Line -0.147
MACD Signal Line 0.0124
MACD Histogram -0.1593
Fundamentals Value
Market Cap 711.59 Million
Num Shares 141 Million
EPS -0.50
Price-to-Earnings (P/E) Ratio -10.12
Price-to-Sales 98.61
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.36
Resistance 3 (R3) 5.36 5.25 5.31
Resistance 2 (R2) 5.25 5.18 5.26 5.29
Resistance 1 (R1) 5.16 5.13 5.11 5.16 5.28
Pivot Point 5.05 5.05 5.03 5.06 5.05
Support 1 (S1) 4.96 4.98 4.91 4.96 4.84
Support 2 (S2) 4.85 4.93 4.86 4.83
Support 3 (S3) 4.76 4.85 4.81
Support 4 (S4) 4.76